Skip to main content
. 2018 Dec 10;9(24):4762–4773. doi: 10.7150/jca.25138

Figure 2.

Figure 2

Effect of siRNA-mediated gene silencing of either MAX or XPO1 on human pancreatic cancer cell proliferation and dasatinib sensitivity. Six human pancreatic cancer cell lines (SU8686, MiaPaCa2, Panc1, BxPc3, Panc0203, Panc1005) were transfected with siRNAs against either MAX or XPO1 (siMAX or siXPO1) and treated with dastainib (10-9 - 10-6 M). A. Without dasatinib treatment, proliferation of siMAX-transfected and siXPO1-transfected cells was compared to siCON-transfected cells by MTT assays. B. siRNA transfected cells were treated with dasatinib (10-9 - 10-6 M), and cell viability was measure by MTT assays. For each cell line, cell growth was normalized to itself without dasatinib treatment. *Values of IC50 were extrapolated from dose curves using Graphpad Prism software.